



Federal Office of Public Health FOPH Public Health Directorate Communicable Diseases Division Schwarzenburgstrasse 157 3003 Berne Switzerland

Geneva, February 09, 2021

N/réf : LK/MS


Geneva Centre for Emerging Viral Diseases

Division of Infectious Diseases

Department of Medicine

SARS-CoV-2 variants: follow-up of previous updates in Geneva

SARS-CoV-2 testing at HUG



Among the Cobas 6800 RT-PCR positive samples, those with a Ct value \leq 32 are used for 501Y and 484K mutations screening by specific RT-PCR assays.


Laboratory of virology

Diagnostic Donatine -+

Division of Laboratory


Medicine

Diagnostic Department



501Y and 484K mutation screening by RT-PCR among SARS-CoV-2 positive samples collected in GE and addressed to our laboratory for primary diagnosis

In addition, Sanger sequencing confirmed the presence of the P.1 variant in two samples collected on January 29, 2021. For one of the two patients, we know that she came back from Brazil a few days before.



Most recent whole genome sequencing results performed on SARS-CoV-2 positive samples collected in GE and addressed to our laboratory

Conclusions

We observe a continuous increase in the percentage of B.1.1.7 variant among SARS-CoV-2 positive samples in the Geneva area, currently around 70%.

A cluster related to the B.1.351 variant identified in a school in Geneva end of January 2021, seems to be under control. Currently, we do not observe an increase in B.1.351 variant detection.

No new P.2 variant-positive sample has been detected since the previous report. Two samples from January 29, 2021, were positive for the P.1 variant.

Writy

Sel

Samuel Cordey

M. hi

Manuel Schibler

Laurent Kaiser